Aktiesnakken — Februar 2012
-
Revenue increased 19% to DKK 111.5 million (DKK 93.5 million): •Organic growth in Life Sciences’ product sales was 36%.
•Life Sciences’ product sales growth is primarily driven by Exqon’s proprietary miRCURY LNA
Universal RT PCR platform for academic and clinical microRNA research. -
Gross profit increased 29% to DKK 62.2 million (DKK 48.1 million):•Exiqon Life Sciences’ gross margin was realized at 51.4% compared to 46.6% in 2010 driven by higher volumes in product sales and lower services revenue in line with strategy.
•Total operating costs decreased 13% to DKK 76.4 million (DKK 88.3 million) excluding special items -
Expectations for 2012: •Following a positive EBITDA in the fourth quarter of 2011 and having achieved its full year guidance for 2011, Exiqon is now on the way to profitability.
•In 2012, Exiqon expects a positive EBIT and positive cash flow from operating activities driven by continued strong growth in research product sales of around 25% (excluding OEM).
•Total revenue is expected around DKK 130 million. -
ser fint ud for exiqon. Væksten fortsætter. Også her i 2012
-
-
-
hvad siger du vil shell købe VWS??
-
reballa.. kan du ikke linke.
-
-
-
haha ja det havde jeg ikke set. det lød også mere end vildt hvis de vil betale 300% præmie
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind